| Literature DB >> 24661344 |
Alexander Weymann1, Tobias Borst, Aron-Frederik Popov, Anton Sabashnikov, Christopher Bowles, Bastian Schmack, Gabor Veres, Nicole Chaimow, Andre Rüdiger Simon, Matthias Karck, Gábor Szabo.
Abstract
BACKGROUND: Infective endocarditis is a life threatening complication of intravenous drug abuse, which continues to be a major burden with inadequately characterised long-term outcomes. We reviewed our institutional experience of surgical treatment of infective endocarditis in active intravenous drug abusers with the aim of identifying the determinants long-term outcome of this distinct subgroup of infective endocarditis patients.Entities:
Mesh:
Year: 2014 PMID: 24661344 PMCID: PMC3994393 DOI: 10.1186/1749-8090-9-58
Source DB: PubMed Journal: J Cardiothorac Surg ISSN: 1749-8090 Impact factor: 1.637
Figure 1Kaplan-Meier survival estimate for IVDU patients with IE who underwent surgical treatment between January 1993 and July 2013.
Patient preoperative demographics
| Age (yrs) | 35.1 ± 7.7 | 34.5 ± 10.6 | 0.926 |
| Female | 6 (33.3%) | 1 (50%) | 0.639 |
| BMI | 23.8 ± 4.7 | 23.1 ± 0.42 | 0.851 |
| Diabetes mellitus | 1 (5.6%) | 0 | 0.732 |
| NYHA stage | 3.28 ± 0.9 | 4.0 ± 0 | 0.005 |
| Renal insufficiency | 5 (33.3%) | 1 (50%) | 0.199 |
| Hepatitis B | 11 (73.3%) | 1 (50%) | 0.496 |
| HIV | 1 (5.6%) | 1 (50%) | 0.047 |
| Previous CVA | 1 (5.6%) | 0 | 0.732 |
| Vegetation | 15 (93.8%) | 2 (100%) | 0.716 |
| Previous endocarditis | 1 (5.6%) | 0 | 0.732 |
| GFR (mL/min/1.73 m2) | 89.2 ± 43.2 | 82.5 ± 82.7 | 0.848 |
| Creatinine (mg/dL) | 1.9 ± 2.4 | 2.3 ± 2.1 | 0.855 |
| Urea (mg/dL) | 73.1 ± 60.4 | 73.5 ± 51.6 | 0.992 |
| GGT (U/L) | 88.4 ± 69.7 | 18.5 ± 0.7 | 0.186 |
| ALT (U/L) | 57.9 ± 43.6 | 10.5 ± 0.7 | 0.154 |
| AST (U/L) | 107.6 ± 121.3 | 258.5 ± 334.5 | 0.182 |
| Bilirubin (mg/dL) | 1.62 ± 3.05 | 0.6 ± 0.35 | 0.636 |
| | | 0.504 | |
| Negative (marantic endocarditis) | 4 (22.2%) | 0 | |
| Staphylococcus aureus | 6 (33.3%) | 2 (100%) | |
| Enterococcus | 2 (11.1%) | 0 | |
| Coagulase negative Staphylococcus | 2 (11.1%) | 0 | |
| Streptococcus species | 4 (22.2%) | 0 | |
| EuroSCORE II | 6.89 ± 3.35 | 11.04 ± 3.35 | 0.036 |
BMI, body mass index; NYHA, New York Heart Association; HIV, human immunodeficiency virus; CVA, cerebrovascular event; GFR, glomerular filtration rate; GGT, gamma glutamyl transpeptidase; ALT, alanine aminotransferase; AST, Aspartate transaminase.
Intraoperative data and postoperative outcomes
| Vegetation size (mm) | 23.5 ± 8.7 | 35 ± 7.1 | 0.099 |
| Bypass time (min) | 130.4 ± 70.9 | 219.5 ± 120.9 | 0.126 |
| Cross clamp time (min) | 86.7 ± 44.4 | 136 ± 84.9 | 0.189 |
| Operation duration (min) | 219 ± 78 | 385 ± 148 | 0.016 |
| | | 0.189 | |
| Mechanical prosthesis | 11 (61.1%) | 0 | |
| Biological prosthesis | 6 (33.3%) | 2 (100%) | |
| Reconstruction | 1 (5.6%) | 0 | |
| | | 0.113 | |
| Aortic | 4 (22.2%) | 0 | |
| Mitral | 2 (11.1%) | 0 | |
| Tricuspid | 7 (38.9%) | 1 (50%) | |
| Aortic and mitral | 2 (11.1%) | 0 | |
| Aortic and tricuspid | 1 (5.6%) | 0 | |
| Mitral and tricuspid | 2 (11.1%) | 0 | |
| Aortic, mitral and pulmonary | 0 | 1 (50%) | |
| 5 (27.8%) | 1 (50%) | 0.521 | |
| RBC (mL) | 1267 ± 883 | 2900 ± 141 | 0.020 |
| FFP (mL) | 433 ± 441 | 200 ± 283 | 0.479 |
| Platelets (mL) | 267 ± 305 | 440 ± 622 | 0.503 |
| Atrial fibrillation | 11 (61.1%) | 2 (100%) | 0.521 |
| AV-block | 4 (23.5%) | 1 (50%) | 0.468 |
| Permanent pacemaker | 2 (11.8%) | 0 | 1.000 |
| Renal failure | 5 (27.8%) | 2 (100%) | 0.111 |
| Coagulation disorder | 3 (17.6%) | 1 (50%) | 0.386 |
| Reopening for bleeding | 0 | 0 | |
| CVA | 0 | 0 |
RBC, red blood cells; FFP, fresh frozen plasma; CVA, cerebrovascular accident.
Figure 2Postoperative white cell count (WCC) course in 90-day survivors vs. 90-day non-survivors. There are no statistically significant differences between the two groups (p = 1.000).
Figure 3Postoperative CRP course in 90-day survivors vs. 90-day non-survivors. There are no statistically significant differences between the two groups (p = 0.275).
Figure 4Postoperative body temperature course in 90-day survivors vs. 90-day non-survivors. Postoperative body temperature was significantly higher in the non-survivor group (p = 0.026) at all time points.